Loading...
Market
Story
GSK and Pfizer to Face 75,000 Zantac Cancer Lawsuits in Delaware, Shares Plunge 10%
Jun 3, 2024, 07:23 AM
GSK and Pfizer are set to face approximately 75,000 lawsuits in Delaware state court over claims that their former heartburn treatment, Zantac, causes cancer. A judge ruled that the evidence supporting these claims can be heard by juries, dismissing GSK's motions to exclude plaintiffs' witnesses. Following the ruling, GSK shares plunged by up to 10%, reflecting investor concerns over the potential impact of the lawsuits on the company.
View original story
Similar markets
Increase • 33%
Decrease • 33%
Remain stable • 34%
Increase • 33%
No significant change • 33%
Decrease • 33%
Less than $1 billion • 33%
$1 billion to $5 billion • 33%
More than $5 billion • 33%
Yes • 50%
No • 50%
GSK wins • 33%
GSK loses • 33%
Settlement reached • 33%
